SGLT2 Inhibitors in Elderly and Frail CKM Patients Consistent benefit across age and frailty, with no excess hypoglycaemia

Authors

  • Dr Ashutosh Mishra english Author

Keywords:

SGLT2 inhibitors, Older adults, Frailty, Hypoglycaemia risk, Heart‑failure hospitalization, Albuminuria, Acute kidney injury, Body composition

Abstract

Abstract
Recent evidence shows SGLT2 inhibitors provide consistent cardiorenal benefits in older and frail patients without excess hypoglycaemia, supporting broader use in CKM populations. A 2026 J Clin Med review found reduced all-cause mortality (RR 0.88), cardiovascular death, heart‑failure hospitalisation (RR 0.72), and MACE (RR 0.87) among adults ≥65 years, with similar or larger absolute benefits in those ≥75. Heart‑failure hospitalisation reductions of 28–34% persisted with advancing age, and frailty did not attenuate efficacy across major trials (DAPA‑HF, DELIVER, EMPEROR‑Preserved, CANVAS/CREDENCE). Safety signals were reassuring: no increased hypoglycaemia, lower albuminuria (RR 0.71), and reduced acute kidney injury (RR 0.70). Practical considerations include monitoring volume status, diuretic adjustment, and attention to nutrition and muscle mass because trials (e.g., EMPA‑ELDERLY) showed modest weight and non‑significant lean‑mass reductions. Older age and frailty should generally prompt initiation rather than withholding of SGLT2 therapy, with individualized clinical judgment for underrepresented very old or nursing‑home populations.

SGLT2 Inhibitors in Elderly and Frail CKM Patients Consistent benefit across age and frailty, with no excess hypoglycaemia Figure 15. SGLT2 Inhibitors in Elderly and Frail CKM Patients — mechanism overview (illustrative; labels added for education). Clinicians often hesitate to prescribe SGLT2 inhibitors in older, frail patients, but a 2026 review in the Journal of Clinical Medicine provides reassurance. In patients aged 65 and older, SGLT2 inhibitors reduced all-cause mortality (RR 0.88, 95% CI 0.83–0.95), cardiovascular death, heart-failure hospitalisation (RR 0.72), and major adverse cardiovascular events (RR 0.87).1 The heart-failure benefit was robust with advancing age: hospitalisation reductions ranged 28–34% in those 65 and older, with similar benefit at 75 and above.1 Strikingly, the MACE benefit was greater in older versus younger patients (HR 0.76, 95% CI 0.62–0.93 per 30-year increase in age), suggesting that older patients may derive more, not less, absolute protection.1 Safety concerns were not borne out. SGLT2 inhibitors did not increase hypoglycaemia risk in older adults, and they reduced albuminuria (RR 0.71) and acute kidney injury (RR 0.70).1 Given how much clinical inertia stems from fear of hypoglycaemia and renal harm, these data directly counter the main objections. Frailty did not blunt efficacy. Benefits were consistent across frailty strata in DAPA-HF, DELIVER, EMPEROR-Preserved, and CANVAS/CREDENCE, and empagliflozin was associated with improvement in frailty status over follow-up—a notable finding in a population where functional decline dominates outcomes.1 The practical implication is a reversal of the usual caution: rather than a reason to withhold therapy, older age may strengthen the case for it, given the larger absolute event reduction and preserved safety.1 Clinicians should still individualise—monitoring volume status, adjusting diuretics, and attending to nutrition and muscle mass given the small lean-mass signal in EMPA-ELDERLY—but frailty per se did not diminish efficacy across the major trials, and empagliflozin was even associated with improved frailty status over follow-up.1 Body composition warrants attention. EMPA-ELDERLY showed a placebo-adjusted body-weight reduction of −2.37 kg (95% CI −3.07 to −1.68; P < 0.001), with non-significant trends toward reduced muscle and lean mass in elderly patients—arguing for attention to nutrition and resistance activity.1 Importantly, the review notes that adults 75 and older remain underrepresented in trials, and no RCTs are specifically designed for frail or nursing-home populations, so individualised judgement still matters.1 On balance, age and frailty are not reasons to withhold this therapy. References 1. Evidence on SGLT2 Inhibitors' Efficacy in Older and Frail Patients, J Clin Med, March 14, 2026 (PMID 41899142). https://pmc.ncbi.nlm.nih.gov/articles/PMC13027104/ 2. Beyond Glucose Control: A Comprehensive Review of SGLT2 Inhibitors, Cureus, March 2, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12952939/ 3. Mechanisms of Action of SGLT2 Inhibitors, Am J Hypertens, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11471837/ 4. 2026 CKM Guideline — Top Things to Know, professional.heart.org, June 9, 2026. https://professional.heart.org/en/science-news/2026-guideline-for-the-prevention-detection-evaluation-and-management-of-ckm-syndrome/top-things-to-know 5. KDIGO 2026 Diabetes and CKD Guideline Update Public Review Draft, March 2026. https://kdigo.org/wp-content/uploads/2026/03/KDIGO-2026-Diabetes-and-CKD-Guideline-Update-Public-Review-Draft-March-2026.pdf 6. Factsheet: The 2026 ADA Standards of Care — What's new?, DiabetesontheNet, Dec 2025. https://diabetesonthenet.com/diabetes-primary-care/factsheet-2026-ada-standards/

Published

2026-07-07

Issue

Vol. 4 No. 15 (2026): SGLT2 Inhibitors in Elderly and Frail CKM Patients Consistent benefit across age and frailty, with no excess hypoglycaemia

Section

Articles

How to Cite

SGLT2 Inhibitors in Elderly and Frail CKM Patients Consistent benefit across age and frailty, with no excess hypoglycaemia. (2026). Diabzen, 4(15), 28-29. https://thediabzen.com/index.php/d/article/view/57

Most read articles by the same author(s)